Jan 10, 2023 8:00am EST Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
Nov 02, 2022 7:00am EDT Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Nov 01, 2022 9:15am EDT Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220
Oct 26, 2022 8:00am EDT Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
Sep 08, 2022 4:01pm EDT Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
Aug 24, 2022 8:00am EDT Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS
Aug 04, 2022 7:00am EDT Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Jul 28, 2022 7:20am EDT Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
